Evidence map›Paper›PMID 27293986›Full record

ArticleAmerican journal of cancer research2016

Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients.

Karolina Jablonska, Jedrzej Grzegrzolka, Marzenna Podhorska-Okolow, Mariusz Stasiolek, Bartosz Pula, Mateusz Olbromski, Agnieszka Gomulkiewicz, Aleksandra Piotrowska, Janusz Rys, Aleksandra Ambicka and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Karolina JablonskaDepartment of Histology and Embryology, Wroclaw Medical University Wroclaw, Poland.
Jedrzej GrzegrzolkaDepartment of Histology and Embryology, Wroclaw Medical University Wroclaw, Poland.
Marzenna Podhorska-OkolowDepartment of Histology and Embryology, Wroclaw Medical University Wroclaw, Poland.
Mariusz StasiolekDepartment of Neurology, Polish Mother's Memorial Hospital-Research Institute Lodz, Poland.
Bartosz PulaDepartment of Histology and Embryology, Wroclaw Medical University Wroclaw, Poland.
Mateusz OlbromskiDepartment of Histology and Embryology, Wroclaw Medical University Wroclaw, Poland.
Agnieszka GomulkiewiczDepartment of Histology and Embryology, Wroclaw Medical University Wroclaw, Poland.
Aleksandra PiotrowskaDepartment of Histology and Embryology, Wroclaw Medical University Wroclaw, Poland.
Janusz RysDepartment of Tumor Pathology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute Cracow Branch, Cracow, Poland.
Aleksandra AmbickaDepartment of Tumor Pathology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute Cracow Branch, Cracow, Poland.
Siew Hwa OngAcumen Research Laboratories, National University of Singapore Singapore.
Maciej ZabelDepartment of Histology and Embryology Poznan, Poland.
Piotr DziegielDepartment of Histology and Embryology, Wroclaw Medical UniversityWroclaw, Poland; Department of Physiotherapy, University School of Physical EducationWroclaw, Poland.
The Maria Sklodowska-Curie National Research Institute of Oncology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies are dedicated to exploring the molecular mechanisms of chemotherapy-resistance in breast cancer (BC). Some of them are focused on searching for candidate genes responsible for this process. The aim of this study was typing the candidate genes associated with the response to standard chemotherapy in the case of invasive ductal carcinoma. Frozen material from 28 biopsies obtained from IDC patients with different responses to chemotherapy were examined using gene expression microarray, Real-Time PCR (RT-PCR) and Western blot (WB). Based on the microarray results, further analysis of candidate gene expression was evaluated in 120 IDC cases by RT-PCR and in 224 IDC cases by immunohistochemistry (IHC). The results were correlated with clinical outcome and molecular subtype of the BC. Gene expression microarray revealed Prolactin-Induced Peptide (PIP) as a single gene differentially expressed in BC therapy responder or non-responder patients (p <0.05). The level of PIP expression was significantly higher in the BC therapy responder group than in the non-responder group at mRNA (p=0.0092) and protein level (p=0.0256). Expression of PIP mRNA was the highest in estrogen receptor positive (ER+) BC cases (p=0.0254) and it was the lowest in triple negative breast cancer (TNBC) (p=0.0336). Higher PIP mRNA expression was characterized by significantly longer disease free survival (DFS, p=0.0093), as well as metastasis free survival (MFS, p=0.0144). Additionally, PIP mRNA and PIP protein expression levels were significantly higher in luminal A than in other molecular subtypes and TNBC. Moreover significantly higher PIP expression was observed in G1, G2 vs. G3 cases (p=0.0027 and p=0.0013, respectively). Microarray analysis characterized PIP gene as a candidate for BC standard chemotherapy response marker. Analysis of clinical data suggests that PIP may be a good prognostic and predictive marker in IDC patients. Higher levels of PIP were related to longer DFS and MFS but not with OS.

Indexed as

adjuvant chemotherapybreast cancerPIP

Identifiers

PMID27293986
PMCPMC4889707
OpenAlexW2417327010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.